Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.8%

1 terminated/withdrawn out of 36 trials

Success Rate

97.1%

+10.6% vs industry average

Late-Stage Pipeline

44%

16 trials in Phase 3/4

Results Transparency

0%

0 of 33 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
14(38.9%)
Phase 3
12(33.3%)
Phase 2
5(13.9%)
Phase 4
4(11.1%)
N/A
1(2.8%)
36Total
Phase 1(14)
Phase 3(12)
Phase 2(5)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials
NCT06091267Phase 1Active Not Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Role: lead

NCT07166796Phase 1Completed

a Phase I PK Study in Healthy Male Subjects. 2 Groups of Healthy Male Subjects

Role: lead

NCT07166783Phase 1Completed

Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol

Role: lead

NCT07166887Phase 1Completed

Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male

Role: lead

NCT05667623Phase 3Completed

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

Role: lead

NCT07105124Phase 1Completed

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Role: lead

NCT03874494Phase 3Completed

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

Role: lead

NCT00511082Phase 1Completed

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Role: lead

NCT04233346Phase 2Active Not Recruiting

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Role: lead

NCT05923892Phase 2Completed

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Role: lead

NCT00823849Phase 4Completed

Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

Role: lead

NCT05583474Phase 3Completed

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

Role: lead

NCT02098460Phase 4Completed

To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject

Role: lead

NCT05650320Phase 3Completed

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

Role: lead

NCT00664014Phase 2Completed

A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Role: lead

NCT03734302Phase 1Completed

The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects

Role: lead

NCT00202007Phase 2Completed

Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

Role: lead

NCT03734354Phase 1Completed

The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects

Role: lead

NCT05439148Phase 1Completed

OPC-61815 in Healthy Chinese Male Subjects

Role: lead

NCT03487783Phase 3Completed

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

Role: lead